SCCA-IgM predicts survival in HCC patients
As reported in the Journal of Gastroenterology & Hepatology, SCCA-IgM levels are elevated in patients with hepatocellular carcinoma (HCC) compared to patients with cirrhosis and healthy controls. Not only does the SCCA-IgM level predict overall and progression-free survival in HCC patients, but the sensitivity of SCCA-IgM in patients with HCC was 2-fold greater than AFP. A decline in SCCA-IgM levels was shown to be associated with response to treatment.
Decreased PTPN12 expression associated with poor prognosis in HCC
As reported in PLoS ONE, the expression of PTPN12 was decreased in hepatocellular carcinoma tissue samples compared with adjacent normal tissues. Furthermore, decreased PTPN12 expression was associated with tumor recurrence, decreased cancer-specific survival, and decreased recurrence-free survival.
Infliximab is effective in corticosteroid-refractory ulcerative colitis
As reported in the Journal of Crohn’s & Colitis, treatment of corticosteroid-refractory ulcerative colitis patients with 3 doses of infliximab (n=113) resulted in short- (3 months) and long-term (12 months) colectomy rates of 18.6% and 25.6%, respectively. The RR of colectomy in patients with an elevated CRP and severe endoscopic lesions was 2.15 and 5.13, respectively.